Status:
COMPLETED
Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.
Lead Sponsor:
Erich Seifritz
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
20-65 years
Phase:
PHASE2
Brief Summary
30 healthy adults and 30 patients with major depressive disorder, will take part in three single-application pharmacological interventions (GHB vs. Trazodone vs. placebo p.o.) to test potential effect...
Eligibility Criteria
Inclusion
- Arm 1 (healthy controls):
- Healthy participants,
- Non-smoker,
- Age 20-65 years
- Arm 2 (patients with depression):
- Diagnosis of major depression (DSM-V),
- Selective Serotonin-Reuptake-Inhibitor (SSRI) or Selective Serotonin-Noradrenalin-Reuptake-Inhibitor (SSNRI) medication,
- Age 20-65 years
Exclusion
Key Trial Info
Start Date :
August 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 6 2022
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04082806
Start Date
August 6 2020
End Date
April 6 2022
Last Update
May 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychiatric University Hospital
Zurich, Canton of Zurich, Switzerland, 8032